92 related articles for article (PubMed ID: 20823048)
1. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.
Hitron A; Steinke D; Sutphin S; Lawson A; Talbert J; Adams V
J Oncol Pharm Pract; 2011 Dec; 17(4):312-9. PubMed ID: 20823048
[TBL] [Abstract][Full Text] [Related]
2. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
[TBL] [Abstract][Full Text] [Related]
3. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
[TBL] [Abstract][Full Text] [Related]
5. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study.
Ten Berg MJ; van den Bemt PM; Shantakumar S; Bennett D; Voest EE; Huisman A; van Solinge WW; Egberts TC
Drug Saf; 2011 Dec; 34(12):1151-60. PubMed ID: 22077503
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer.
Wosnitzer MS; Hruby GW; Murphy AM; Barlow LJ; Cordon-Cardo C; Mansukhani M; Petrylak DP; Benson MC; McKiernan JM
Cancer; 2012 Jan; 118(2):358-64. PubMed ID: 21717438
[TBL] [Abstract][Full Text] [Related]
10. Update on chemotherapy for advanced bladder cancer.
Rosenberg JE; Carroll PR; Small EJ
J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
[TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
15. Urological implications of concurrent bladder and lung cancer.
Vainrib M; Leibovitch I
Isr Med Assoc J; 2007 Oct; 9(10):732-5. PubMed ID: 17987763
[TBL] [Abstract][Full Text] [Related]
16. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice.
Weycker D; Hatfield M; Grossman A; Hanau A; Lonshteyn A; Sharma A; Chandler D
BMC Cancer; 2019 Feb; 19(1):151. PubMed ID: 30764783
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in lung cancer patients].
Xu YH; Chen ZW; Ye XY; Lu S
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):716-9. PubMed ID: 19173920
[TBL] [Abstract][Full Text] [Related]
18. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
Milman S; Kim AW; Warren WH; Liptay MJ; Miller C; Basu S; Faber LP
Ann Thorac Surg; 2009 Sep; 88(3):945-50; discussion 950-1. PubMed ID: 19699925
[TBL] [Abstract][Full Text] [Related]
19. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.
Elting LS; Rubenstein EB; Martin CG; Kurtin D; Rodriguez S; Laiho E; Kanesan K; Cantor SB; Benjamin RS
J Clin Oncol; 2001 Feb; 19(4):1137-46. PubMed ID: 11181679
[TBL] [Abstract][Full Text] [Related]
20. The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China.
Zhou S; Song B; Li C; Tang W; Zhang X; Jin X; Xu X; Wang Q; Zheng H; Fu J
Sci Rep; 2023 Feb; 13(1):3185. PubMed ID: 36823199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
